TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This Phase 2, double‐blind, randomized, multicenter, parallel, controlled study is conducted to evaluate safety, tolerability, pharmacokinetics and efficacy of TNP‐2092, and vancomycin in adults with ABSSSI suspected or confirmed to be caused by gram‐positive pathogens. The duration of the treatment period is a minimum of 7 days and a maximum of 14 days.
Epistemonikos ID: 578bab8703b86ce9bc4a800cbe859fcf75c28d72
First added on: May 22, 2024